Empagliflozin/Linagliptin and Dolutegravir Interaction
Drug interaction information between Empagliflozin/Linagliptin and Dolutegravir.
Empagliflozin/Linagliptin and Dolutegravir have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Empagliflozin/Linagliptin and Dolutegravir. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.
How They Interact
Dolutegravir blocks the kidneys from filtering metformin out of your blood, which makes metformin levels rise. Higher levels of metformin increase the risk of a serious health problem called lactic acidosis.
FDA Label Information
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Empagliflozin/Linagliptin Also Interacts With
- Metformin moderate
- Ranolazine moderate
- Cimetidine moderate
- Empagliflozin minor
- Topiramate minor
Dolutegravir Also Interacts With
- Dofetilide major
- Empagliflozin moderate
- Ertugliflozin moderate
- Linagliptin moderate
- Metformin/Empagliflozin moderate
Frequently Asked Questions
What SPL severity band is on file for Empagliflozin/Linagliptin + Dolutegravir?
Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.
Which drug in this pair has the larger labeled-interaction portfolio?
Dolutegravir has 28 labeled pairs on file vs Empagliflozin/Linagliptin's 11. In the moderate band specifically: Empagliflozin/Linagliptin has 4 (also Metformin, Ranolazine, Cimetidine); Dolutegravir has 6 (also Empagliflozin, Ertugliflozin, Linagliptin, Metformin/Empagliflozin).
What mechanism field is on file for Empagliflozin/Linagliptin and Dolutegravir?
Dolutegravir blocks the kidneys from filtering metformin out of your blood, which makes metformin levels rise. Higher levels of metformin increase the risk of a serious health problem called lactic acidosis.
Dolutegravir carries more major-labeled pairs than Empagliflozin/Linagliptin
SPL source-record counts only. This page's band is moderate · classes on file: Empagliflozin/Linagliptin (SGLT2 / DPP-4 Combination); Dolutegravir (Integrase Strand Transfer Inhibitor).
Dolutegravir has 1 major-labeled pair vs Empagliflozin/Linagliptin's 0. This page itself is in the moderate band, not the major band.
0 major · 4 moderate · 7 minor · 11 total
- Other moderate peers for Empagliflozin/Linagliptin
- Metformin
- Ranolazine
- Cimetidine
1 major · 6 moderate · 21 minor · 28 total
- Other moderate peers for Dolutegravir
- Empagliflozin
- Ertugliflozin
- Linagliptin
- Metformin/Empagliflozin
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.
Read our methodology - how this data is sourced, computed, and verified.